Opiate-induced pupillary effects in humans.

The pupillary effects of several opiates were assessed in human volunteers (N = 6) by means of a newly developed hand-held pupilometer, Pupilscan. Static (diameter) and dynamic (light reflex) responses after morphine, heroin, codeine, oxycodone, oxymorphone and hydrocodone were recorded. The opiates caused dose-related decreases in pupillary size and in the velocity of constriction to a light stimulus.

Spontaneous EEG changes during tobacco abstinence and nicotine substitution in human volunteers.

Electroencephalographic correlates of tobacco abstinence and nicotine substitution were measured in adult male cigarette smokers in residence on a research ward in two experiments. After ad libitum smoking, seven subjects were deprived of nicotine for 10 days and then resumed smoking. During tobacco abstinence, there were significant decreases in alpha frequency and beta frequency and increases in theta power.

Dose-dependent effects of atropine on behavioral and physiologic responses in humans.

Atropine is an antimuscarinic which has been frequently studied with learning and performance tasks using both human and animal subjects. However, interpretation of data from human studies is limited by the relatively narrow range of doses used in most such studies. In the present study a wide range of atropine doses (0, 1.

Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction.

A new, rapid dose-induction procedure was used in the evaluation of buprenorphine hydrochloride (buprenorphine) as a treatment for opiate dependence. Nineteen heroin-dependent men were given buprenorphine sublingually in ascending daily doses of 2, 4, and 8 mg and then maintained on 8 mg daily. The observations of the transition from heroin to buprenorphine for the first 4 days are described.

The tobacco withdrawal syndrome: performance decrements assessed on a computerized test battery.

The effects of tobacco abstinence and resumption of smoking on cognitive performance were studied in seven cigarette smokers. Subjects were trained on a computerized performance assessment battery (PAB) that included five different tests. Baseline data were obtained under conditions of minimally restricted cigarette smoking.

Mecamylamine increases nicotine preference and attenuates nicotine discrimination.

Eight subjects evaluated various qualities of cigarette smoke after being given a range of doses (0, 2.5, 10 and 20 mg) of the nicotinic receptor blocker mecamylamine. In one test condition, subjects were given either high or low nicotine tobacco smoke to determine the effects of mecamylamine on their subjective responses.

Effects of atropine on the repeated acquisition and performance of response sequences in humans.

The present study assessed a 24-hr time course for the acute effects of intramuscular injections of atropine sulfate (0, 1.5, 3.0, and 6.

An interpretative review of smokeless tobacco research in the United States: Part II.

This is the second part of a two-part series reviewing the published literature of smokeless tobacco in the United States. The article explores smokeless tobacco as a pharmacologically addicting substance, educational interventions designed to prevent use or help users quit, and outlines areas of future research.

Effects of nicotine administration following 12 h of tobacco deprivation: assessment on computerized performance tasks.

The purpose of this study was to assess the effects of acute nicotine administration, following a 12-h cigarette deprivation period, using a computerized performance assessment battery (PAB). The PAB was comprised of five tasks which were selected to reflect a variety of complex acquired behaviors, sometimes referred to as "cognitive performance". Subjects were six healthy, male, cigarette smokers who practiced on the approximately 15 min PAB until their performance was stable across trials.

Mecamylamine reduces some EEG effects of nicotine chewing gum in humans.

Spontaneous EEG was recorded in nine cigarette smokers who had been abstinent from tobacco for 12 hr. Subjects were treated with a capsule containing either centrally acting nicotine blocker, mecamylamine (10 mg), or placebo. At each of three 60-min intervals after the capsule was ingested, the subjects chewed two pieces of gum containing a total of 0, 4 or 8 mg of nicotine.

Pharmacological treatment of tobacco dependence.

Pharmacologically based approaches for the treatment of tobacco dependence are reviewed. The rational basis for pharmacologic treatment approaches is that tobacco dependence is partially, and critically, mediated by the actions of tobacco-delivered nicotine to the central nervous system. These actions include direct reinforcing properties of nicotine itself, tolerance and physiologic dependence, possible beneficial effects of nicotine in the alleviation of anxiety and control of weight, and neurohormonal regulation which can become important to the maintenance of emotional well-being and performance at work.

Reinforcing effects of nicotine in humans and experimental animals responding under intermittent schedules of i.v. drug injection.

The self-administration paradigm is an experimental model of drug dependence in which the reinforcing properties of drugs can be directly assessed. This paradigm avoids the possible confounding influence of nonpharmacologic factors which may contribute to drug taking in the nonlaboratory environment. When animals serve as subjects, social and cultural factors unique to humans may also be eliminated as confounding influences.

Pharmacologic determinants of tobacco self-administration by humans.

Tobacco is a naturally occurring source of nicotine, which is a chemical of demonstrable abuse liability and dependence potential. All commonly used forms of tobacco result in the delivery of nicotine to the central nervous system (CNS), where its actions affect the probability of subsequent use. The role of nicotine as a determinant of patterns of tobacco self-administration and other tobacco-associated responses has frequently been confounded by the complexity of this form of drug self-administration, since the amount of nicotine delivered to the CNS is not a simple function of the amount of tobacco consumed.

Progress in understanding the relationship between the pharmacological effects of nicotine and human tobacco dependence.

The present paper is intended to serve as an introduction to the series of eight papers which follow in this issue of Pharmacology Biochemistry and Behavior. A brief historical review of research that is at the root of much recent progress is provided in the present paper. In addition, we provide some data which illustrates the scope of tobacco-related research, world wide, in an effort to provide a perspective as to the vast amount of research activity that is currently in progress.

Nicotine gum: chew rate, subjective effects and plasma nicotine.

Two studies were conducted to assess the effects of varying the rate at which single pieces of nicotine gum (4 mg) were chewed. In each study, six cigarette-deprived volunteers were tested during four sessions. In each session, they were required to chew the gum for 10 min at varying rates; a variety of self-report and physiologic responses were recorded before and after chewing.